Skip to main content
TipRanks
Go Ultimate75% OFF

STELLA PHARMA CORPORATION (4888) AI Stock Analysis

0 Followers
JP:4888

STELLA PHARMA CORPORATION

(TSE/TYO:4888)

Select Model
Rating:49Neutral
Price Target:JPY 389.00â–¼(-0.51% Downside)
Action:reiterated
Date:11/18/26

STELLA PHARMA CORPORATION scores a 49, reflecting a speculative investment profile. The most significant risks stem from deep unprofitability, recurring cash burn, and weak valuation metrics. However, strong technicals—with the stock trading above all major moving averages—and a conservative, low-debt balance sheet offer some positive structural support.

Positive Factors
High Gross MarginsGross margins of roughly 77%–90% indicate attractive underlying economics in the company’s offerings, even though operating costs currently prevent profitability. If revenue stabilizes, this margin structure could provide meaningful operating leverage and support a path toward improved earnings over the next several quarters.
Negative Factors
Sharp Revenue ContractionThe sharp 2026 revenue contraction, following much stronger 2025 performance, demonstrates weak top-line visibility and substantial business volatility. Unpredictable revenue makes staffing, investment, and cash planning more difficult, while also reducing confidence that the company can sustain growth without additional funding.

STELLA PHARMA CORPORATION (4888) vs. iShares MSCI Japan ETF (EWJ)

-50%0%50%100%150%200%250%300%JP:4888+61.57%EWJ+6.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 14.87B
Dividend Yield
―
Average Volume (3M)
760.20K
Price to Earnings (P/E)
-14.4
Beta (1Y)
0.85
Revenue Growth
-69.92%
EPS Growth
-411.54%
Country
Japan
Employees
47
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

STELLA PHARMA CORPORATION Business Overview & Revenue Model

Company Description

Stella Pharma Corporation is a pharmaceutical company that handles the complete process of drug development, from research and manufacturing to distribution. A core area of its specialization is in therapeutic agents for boron neutron capture therapy...

STELLA PHARMA CORPORATION Financial Statement Overview

Summary

Exhibits a highly speculative profile typical of the biotechnology sector. A well-managed balance sheet with low debt and conservative leverage is heavily offset by erratic revenue, deeply negative profit margins (-241.5%), and recurring operational cash burn.

Income Statement

25Negative

Balance Sheet

65Positive

Cash Flow

35Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue323.39M323.39M961.06M269.49M229.07M100.10M
Gross Profit264.07M250.56M828.72M203.69M192.36M50.73M
EBITDA-832.87M-742.15M-99.06M-723.85M-738.35M-726.86M
Net Income-853.06M-780.92M-140.81M-763.75M-778.82M-767.72M
Balance Sheet
Total Assets5.39B4.49B5.42B3.82B4.33B4.72B
Cash, Cash Equivalents and Short-Term Investments3.80B2.82B3.21B2.35B2.71B3.28B
Total Debt899.48M747.14M766.78M933.30M1.09B1.25B
Total Liabilities2.17B2.06B2.21B1.44B1.58B1.64B
Stockholders Equity3.22B2.43B3.21B2.38B2.75B3.08B
Cash Flow
Free Cash Flow0-345.32M136.50M-887.82M-853.07M-1.13B
Operating Cash Flow0-334.51M140.41M-876.84M-827.67M-1.08B
Investing Cash Flow0-15.67M287.58M-9.01M-29.93M-350.56M
Financing Cash Flow0-33.28M725.78M228.25M291.69M3.46B

STELLA PHARMA CORPORATION Technical Analysis

Technical Analysis SentimentNegative
Last Price391.00

Price Trends

50DMA406.52Negative
100DMA365.88Positive
200DMA421.70Negative

Market Momentum

MACD2.92Negative
RSI48.50Neutral
STOCH70.96Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4888, the sentiment is Negative. The current price of 391.00 is below the 20-day moving average (MA) of 395.30, below the 50-day MA of 406.52, and below the 200-day MA of 421.70, indicating a bearish trend. The MACD of 2.92 indicates Negative momentum. The RSI at 48.50 is Neutral, neither overbought nor oversold. The STOCH value of 70.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4888.

STELLA PHARMA CORPORATION Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:4888 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4888JP:488849NeutralJPY 14.87B-14.45――-69.92%-411.54%
JP:7774JP:777442NeutralJPY 25.18B-70.06――17.05%10.47%
JP:4571JP:457141NeutralJPY 5.92B-4.14-39.57%―48.92%-46.91%
JP:4599JP:459939UnderperformJPY 7.65B-4.11―――4.85%
JP:4593JP:459337UnderperformJPY 26.84B-11.95――-51.55%52.19%

* Healthcare Sector Average

Performance Comparison

0%100%200%JP:4888JP:4571JP:4593JP:4599JP:7774Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4888 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4888STELLA PHARMA CORPORATION391.00149.0061.57%
JP:4571NanoCarrier Co., Ltd.65.00-79.00-54.86%
JP:4593Healios KK198.00-269.00-57.60%
JP:4599StemRIM Inc.122.00-157.00-56.27%
JP:7774Japan Tissue Engineering Co., Ltd.620.00134.0027.57%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 18, 2026